PUBLIC PERSPECTIVES ON PERSONALIZED MEDICINE

Similar documents
July Prepared for

STATE AND COMMUNITY MODELS FOR IMPROVING ACCESS TO DENTAL CARE FOR THE UNDERSERVED

Drugs for Rare Disorders

54% 23% 22% Administrators perceive student marijuana use is on the rise. The MassINC Polling Group 1. October 17, the same

Communicating with Your Healthcare Team

Americans Views on Vaccines and Infectious Disease Outbreaks

Building a Personalized. Medicine Program. Title & Subtitle can knockout of image. 22 September October 2015 OI

Commonly asked questions about genetic testing for hereditary cancer

Health Care Reform Update and Advocacy Priorities

Limited English Proficiency Training

Cost-effectiveness, Affordability, and Financing of Cervical Cancer Prevention

Virtual Mentor American Medical Association Journal of Ethics June 2007, Volume 9, Number 6:

Everyone Loves Birth Control

Things You Must Know Before Choosing An

Lia Hotchkiss: I'm Lia Hotchkiss and I'm with the Agency for Healthcare. Research and Quality. We are one of the 12 agencies part of the Department of

2015 Survey on Prescription Drugs

Minority populations are hardest hit by diabetes. Join us to Stop Diabetes in your community!

61 Recommendations for better use of medications

CHC Oral Health Programs & Primary Care Associations: Working together to create policy change & state partnerships

Task Force Finding and Rationale Statement

our aberlour Supporting Children and Families Earlier

What do we mean by brand value (innovation) within the pharmaceutical sector? Biomedicine Master Program, Lund University, Sweden

TumorNext-HR D. patient guide. a test for ovarian cancer patients to identify hereditary and tumor-specific mutations

STATEMENT. of the. American Medical Association. for the Record. House Committee on Energy and Commerce

Learning about Conflict

MNPS Hearing Service Plan Employee Booklet 2015 HEAR BETTER LIVE FULLY. epichearing.com

Higher Risk, Lowered Age: New Colorectal Cancer Screening Guidelines

Getting on Insurance Panels

DEKALB COUNTY GOVERNMENT DRUG-FREE WORKPLACE POLICY

Invisible Islington: living in poverty in inner London Executive summary of a report for Cripplegate Foundation by Rocket Science (UK)

Ebola Risk Perception Survey. Top Line Report OVERVIEW

Clinical Trials: Improving the Care of People Living With Cancer

Death and Dying in California

A Call to Action. Paths to Recovery. Faces & Voices of Recovery. Governance Structure. Recovery Community. Many Voices, A Common Message

Insurance Guide For Dental Healthcare Professionals

1 DENTAL CARE FOR SENIORS

416 DRUG AND ALCOHOL TESTING I. PURPOSE

FOREWORD: PREDICTIVE HEALTH TECHNOLOGIES

Restrictions to HCV Treatment in State Medicaid Programs

I m NOT Interested in Anything I m NOT Interested In!!

CONFERENCE SUMMARY. An Overview of Challenges and Solutions in Science, Business and Policy

Alliance for Aging Research Key Findings from Public Survey on Early Alzheimer's Diagnosis

DRAFT: Sexual and Reproductive Rights and Health the Post-2015 Development Agenda

Release # For Publication: Wednesday, June 21, 2017

New Challenges and New Horizons: How do we move forward with hospice palliative care? Sharon Baxter, Executive Director May 5 th, 2016 Vancouver, BC

Good enough? Breast cancer in the UK

July 6, Scott Gottlieb, MD Commissioner U.S. Food and Drug Administration New Hampshire Avenue Silver Spring, MD 20993

It s an exciting time for pharmaceutical companies in the. Oncology Reps New Mantra: Provide Real Value, Maintain Physician Access

Embracing Precision Medicine: How to Improve Health and Be Able to Afford It

Year Strategy. Our purpose is to end homelessness

Trends in the Development of the Dental Service Organization (DSO) Model: Implications for the Oral Health Workforce and Access to Services

Citizens Jury Questionnaire Results

January 2, Dear Technical Review Committee Members:

Are You Considering Using CAM?

The Important Role of Advocacy. The Challenge of Governance

FINAL TOPLINE. Diabetes Group. Qualities That Matter: Public Perceptions of Quality in Diabetes Care, Joint Replacement and Maternity Care

Executive Summary. Burton Edelstein DDS MPH. Donald Schneider DDS MPH. R. Jeffrey Laughlin MPH

DEMAND FOR DIABETES PREVENTION PROGRAMS. A Feasibility Study

Changing Public Behavior Levers of Change

February, 20, Senator Orrin G. Hatch Senator Ron Wyden U.S. Senate Committee on Finance Washington, DC Dear Senators Hatch and Wyden,

THE GROWTH OF SPECIALTY PHARMACY

Patient-Centered Oncology Payment: Payment Reform to Support Higher Quality, More Affordable Cancer Care (PCOP)

Evidence based assessment of the value of innovation: pricing solutions and prospects

Advances in Oral Cancer: Applications in Public Health

Pharmaceutical Liability Study Report on Findings

Tackling doping in sport: a call to take action on the dopogenic environment. Susan H. Backhouse, Claire Griffiths & Jim McKenna

Agenda 2030: One Nation Labour s Plan for science Response from Alzheimer s Research UK

DIABETES TEST STRIPS REIMBURSEMENT REDUCTIONS TO INDEPENDENT PHARMACIES WILL NEGATIVELY IMPACT MEDICARE PATIENTS

10 Good Reasons Why Women Should Vote in 2004

GOOD MEDICINE COMMUNITY ACUPUNCTURE

Breast Cancer Network Australia Breast Care Nurse Breast Reconstruction Survey September 2011

REPORT OF THE COUNCIL ON MEDICAL SERVICE

Vanderbilt University Institutional Review Board Informed Consent Document for Research. Name of participant: Age:

Co-operative Clinical Trials in Cancer the need for increased capacity

Working with Policymakers and Payers to Improve the Incentives for ADFs. Dan Cohen Forum Chair - Abuse Deterrent Coalition

Children and Adults with Attention-Deficit/Hyperactivity Disorder Public Policy Agenda for Adults

ASSOCIATION OF WOMEN SOLICITORS, LONDON. Response to SRA Consultation: A Question of Trust

FACT SHEET: Federal Parity Task Force Takes Steps to Strengthen Insurance Coverage for Mental Health and Substance Use Disorders

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis

SPECIAL REPORT: CPT CODES WHAT THERAPISTS NEED TO KNOW

Protecting the Future of Oncology Care A Community Conversation. Presentations by:

The dramatic growth of managed. Use of Psychiatrists, Psychologists, and Master s-level Therapists in Managed Behavioral Health Care Carve-Out Plans

FAMILY & CHILDREN S SERVICES STRATEGIC PLAN

FOR YOUR ADVOCATING DIABETES NEEDS. Moving Forward. DOI: By Melissa Lee and Martin Wood

Comment Number. Date Comment Received

EHR Developer Code of Conduct Frequently Asked Questions

Van Biljon and Others v Minister of Correctional Services and Others 1997 (4) SA 441 (C) (SAHC 1997 C)

Strategies for Using Pre-Exposure Prophylaxis (PrEP) to Lower HIV Incidence in Select Populations

Adoption of Genomics in Oncology Care

Get an Insurance Benefits Review for ORENCIA (abatacept)

Conversations: Let s Talk About Bladder Cancer

Collective Impact in Health

Strategy Challenging homelessness. Changing lives.

Evaluation of Satellite Clubs: FINAL REPORT

Presentation Preparation

10m Appeal DELIVERING FASTER, WORLD-CLASS SCANS. Beyond the NHS promise of care

Pink Is Not Enough Breast Cancer Awareness Month National Breast Cancer Coalition Advocate Toolkit

2018 Edition The Current Landscape of Genetic Testing

LAWS OF ALASKA AN ACT

Quad Cities July 3, 2008

Transcription:

PUBLIC PERSPECTIVES ON PERSONALIZED MEDICINE A Survey of U.S. Public Opinion MAY 2018 Conducted for Conducted by

2 Public Perspectives on Personalized Medicine KEY FINDINGS 1. Most Americans are not familiar with personalized medicine. The vast majority want to learn more about it. 2. When personalized medicine is described to Americans, most are excited about the field s potential. 3. Most Americans believe insurance companies should pay for personalized tests and treatments. 4. Some Americans have concerns about personalized medicine. Most of these concerns are related to insurance coverage, costs and the potential for discrimination based on personal health data. Most are not aware of the privacy protections in place to protect patients from discrimination.

Public Perspectives on Personalized Medicine 3 A NEW PARADIGM Personalized medicines now account for one of every four new drugs approved by the U.S. Food and Drug Administration (FDA). Each of these products is designed for a small population of patients that is highly likely to benefit from the treatment based on the presence of measurable biological characteristics. As such, the therapies are designed to increase the percentage of patients who are actually helped by the treatments they are prescribed, making health care more efficient and effective. But because personalized medicines and the tests needed to inform their use break the mold of a health system that was optimized to deliver medicine based on population averages, the incoming wave of personalized medicines presents challenges related to regulation, reimbursement and clinical adoption. These challenges are often compounded by the fact that personalized medicine presents a different value proposition than the traditional one-size-fits-all model. Understanding the extent to which the American public is informed about and supportive of the personalized medicine paradigm can thereby help decision-makers in the public and private sectors consider and communicate about policies and practices that may influence the pace at which personalized medicines are integrated into the health system. To better understand the American public s perspectives on personalized medicine, the Personalized Medicine Coalition and GenomeWeb commissioned KRC Research to conduct a representative survey of 1,001 Americans in the Spring of 2018 to measure awareness of and opinions about the field and its stated benefits. The results of the survey demonstrate that most Americans are not familiar with the concept of personalized medicine. After reviewing information about its benefits, however, the majority of Americans are excited about the field and want to learn more about it. Most believe insurance companies should cover personalized tests and treatments. Some have concerns about the field, which are often related to insurance coverage, costs and the potential for discrimination based on health data. Most are not aware of the Genetic Information Nondiscrimination Act, which prohibits the use of genetic data for certain discriminatory purposes.

4 Public Perspectives on Personalized Medicine LIMITED AWARENESS Most Americans are Not Familiar with Personalized Medicine Most Americans are not familiar with personalized medicine. Sixty-six percent of adults living in the United States say they have never heard or read anything about personalized medicine or precision medicine. Among those who have heard of it, only 13 percent feel very informed about the topic. Only 9 percent of respondents said they had heard of the federal government s flagship program in personalized medicine, called the All of Us Research Program, and only 10 percent said a medical provider has recommended a genetic test to them. Seventeen percent have heard of genetic counseling, but only 4 percent have spoken to a genetic counselor. The vast majority of respondents want to learn more about personalized medicine. In fact, 82 percent of U.S. adults reported an interest in more information about the field, and 32 percent said they are very interested. The vast majority of respondents want to learn more about personalized medicine. In fact, 82 percent of U.S. adults reported an interest in more information about the field.

Public Perspectives on Personalized Medicine 5 Most Americans Have Not Heard of Either Personalized Medicine or Precision Medicine 66% 34% 66% of Americans have NOT heard of either personalized medicine or precision medicine 34% of Americans have heard of either personalized medicine or precision medicine These results were derived from the following question: Which of the following terms have you heard or read something about prior to today? Please select all that apply. Personalized medicine Precision medicine

6 Public Perspectives on Personalized Medicine POSITIVE REACTIONS When Personalized Medicine is Described to Americans, Most are Excited About Its Potential Once they learn about personalized medicine, most Americans are enthusiastic about its potential. In fact, 67 percent of respondents reacted positively to a description of the field. Thirty-two percent were neutral. Only one percent reacted negatively. Description of Personalized Medicine Personalized medicine, sometimes referred to as precision medicine, is an emerging field that uses diagnostic tools to identify specific biological markers, often genetic, to help determine which medical treatments and procedures will be best for each patient. By combining this information with an individual s medical records and circumstances, personalized medicine allows doctors to develop targeted prevention and treatment plans. The goal is to provide the right treatment in the right dose to the right patient at the right time.

Public Perspectives on Personalized Medicine 7 Most Americans React Positively to a Description of Personalized Medicine 1% 32% 32% of Americans have a neutral reaction 67% 67% of Americans have a mostly positive reaction 1% of Americans have a mostly negative reaction These results were derived from the following question: What is your reaction to the description of personalized medicine?* Mostly positive Neutral Mostly negative *See description at left

8 Public Perspectives on Personalized Medicine SUPPORT FOR COVERAGE Seeing Major Benefits, Most Americans Believe Insurers Should Cover Personalized Medicine Most Americans believe health insurance companies should cover personalized tests and treatments. Two-thirds (67 percent) believe personalized tests and treatments should be covered. The other third believes payers should not cover personalized medicine because health care costs are already too high. Those who are over age 65 and those who have faced or had a loved one face a life-threatening disease are more likely to believe that the tests and treatments should be covered. The support for coverage likely reflects the fact that most Americans are excited by the potential of personalized medicine. Survey respondents saw major benefits, for example, in opportunities to improve upon the trial-and-error treatment process (70 percent), reduce the need for invasive procedures (67 percent), reduce adverse side effects (65 percent) and shift the emphasis in medicine from reaction to prevention (64 percent). The support for coverage likely reflects the fact that most Americans are excited by the potential of personalized medicine.

Public Perspectives on Personalized Medicine 9 Most Americans Believe Insurance Companies Should Cover Personalized Tests and Treatments 67% 33% 67% of Americans believe insurance companies should cover personalized tests and treatments 33% of Americans believe insurance companies should NOT cover personalized tests and treatments These results were derived from the following question: Because personalized tests and treatments are targeted to a small number of patients, they are sometimes more expensive than conventional tests and treatments. With that in mind, read these two statements. Of the two statements, which one is closest to your own personal opinion? Personalized tests and treatments deliver more value to patients and may help control overall health care spending by avoiding the trial-and-error process currently used to find a treatment that works for each patient. Therefore, health insurance companies should cover these tests and treatments. Personalized medicine is promising, but health care costs are already high and some of these new tests and treatments are too expensive. In order to keep health care affordable, health insurance companies should not cover these personalized tests and treatments.

10 Public Perspectives on Personalized Medicine EMERGING CONCERNS Some Americans Have Coverage, Affordability and Privacy Concerns Related to Personalized Medicine Although most Americans had no worries about personalized medicine when asked, 44 percent raised questions related to topics including side effects, safety and privacy of personal genetic information. When shown a list of known concerns, most said they have major concerns that a test might not be covered by their insurer (62 percent), they might not be able to afford personalized medicine (59 percent), or that test results could be used to deny coverage for a treatment (52 percent) or affect long-term care or life insurance policies (51 percent). Only 10 percent of Americans indicated that they are aware of the Genetic Information Nondiscrimination Act, which prohibits employers or health insurers from asking for genetic test results when making employment or coverage decisions. Although most Americans had no worries about personalized medicine when asked, 44 percent raised questions related to topics including side effects, safety and privacy of personal genetic information.

Public Perspectives on Personalized Medicine 11 Americans Cite Major Concerns Related to Access, Cost and Privacy The test might not be covered by my insurer. 62% The test could be used to deny coverage for a treatment I want. 52% I might not be able to afford a personalized approach to health care. 59% Information about my risk for developing a disease in the future could be used to deny long-term care or life insurance that I need. 51% Americans Expressing Major Concern These results were derived from the following question: Here are some reasons some people give for why they worry about personalized medicine. For each one, please indicate how much of a concern it would be for you personally. [CHOICES: Major Concern; Minor Concern; Not a Concern; Not Sure] The test might not be covered by my insurer. The test could be used to deny coverage for a treatment I want. I might not be able to afford a personalized approach to health care. Information about my risk for developing a disease in the future could be used to deny long-term care or life insurance that I need.

12 Public Perspectives on Personalized Medicine CONCLUSION Strong Public Support for Personalized Medicine The survey results show strong public support for personalized medicine. Americans are quick to recognize the shortcomings of the trial-and-error processes by which most treatment decisions are made today, and see value in tools that can quickly identify which treatment is right for a patient. Influenced but undeterred by cost and privacy concerns, most Americans believe the benefits of personalized medicine warrant coverage of tests and treatments even when they are associated with higher up-front costs. The results indicate that innovative efforts on behalf of policymakers to facilitate greater access to personalized medicine would be well-received by the American public. They also point to a need for public education about the field, particularly as new personalized medicines enter the market. The results indicate that innovative efforts on behalf of policymakers to facilitate greater access to personalized medicine would be well-received by the American public.

Public Perspectives on Personalized Medicine 13

14 Public Perspectives on Personalized Medicine ABOUT US The Personalized Medicine Coalition (PMC), representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. GenomeWeb is an independent online news organization based in New York. Since 1997, GenomeWeb has served the global community of scientists, technology professionals, and executives who use and develop the latest advanced tools in molecular biology research and molecular diagnostics.

Public Perspectives on Personalized Medicine 15

16 Public Perspectives on Personalized Medicine www.personalizedmedicinecoalition.org pmc@personalizedmedicinecoalition.org 202-589-1770 @PerMedCoalition www.genomeweb.com customerservice@genomeweb.com 212-269-4747 @GenomeWeb